The major factors for improving final adult height in girls with Turner syndrome treated with recombinant human growth hormone and Stanazolol

Abstract

Objective To analyze the major factors for improving final adult height (FAH) in girls with Turner syndrome (TS) treated with recombinant human growth hormone (rhGH) and Stanazolol(ST). Methods The FAH of 64 girls with TS who were admitted into the First Affiliated Hospital of Sun Yat-Sen University from June 1998 to June 2013 were investigated.Among them, 38 cases had received rhGH and ST for 0.6-5.5 years (treatment group), their chronological age (CA0) was (12.7±2.5) years(6.8-18.4 years), and the course of the treatment was (2.8±1.3) years(0.6-5.5 years); the other 26 girls without rhGH therapy were considered as the non-treatment group.The factors determining FAH were evaluated. Results (1) Compared with the non-treatment group, FAH in the treatment group was significantly higher[(149.4±5.9) cm vs (136.7±5.0) cm, t=9.001, P 0.05). (3)Besides, the treatment group was then divided into 5 subgroups receiving different duration of therapy: the 0.6-0.9 years, 1.0-1.9 years, 2.0-2.9 years, 3.0-3.9 years and 4.0-5.8 years group.The mean FAH of the 2.0-2.9 years, 3.0-3.9 years and 4.0-5.8 years group was within normal height range of healthy Chinese female.(4)In treatment group, FAH was positively correlated with genetic target height SDS(THtSDS), height SDS at the initiation of therapy (Ht0SDS), the duration of rhGH+ ST therapy and growth velocity at the first year of treatment (r=0.464, 0.753, 0.532 and 0.428, all P<0.01), and was negatively correlated with CA0(r=-0.466, P<0.01). Step wise regression analysis indicated that Ht0SDS, the duration of rhGH+ ST therapy and THtSDS was the variables with the greatest identified influence on FAH (F=47.27, 14.25, 9.86, all P<0.01). Conclusions Combined rhGH and ST treatment can effectively improve FAH in girls with TS.For TS girls with CA0 less than 16 years old, they may obtain satisfied FAH in 2 years' rhGH+ ST therapy.Ht0SDS, duration of rhGH+ ST therapy and THtSDS determine FAH. Key words: Turner syndrome; Human growth hormone, recombinant; Stanazolol; Adult height; Factors